

HellerEhrman
ATTORNEYS**FACSIMILE COMMUNICATION****IMPORTANT NOTICE**

The information accompanying this facsimile transmission is intended for the use of the recipient named below only. The information may contain confidential information which may be legally privileged. If you have received this facsimile in error, please notify us by telephone immediately to arrange for return of the original documents to us. Any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited.

TELECOPIER NO.: 703-746-5339

TO: Examiner Schwadron

FROM: Stephanie Seidman

DATE: April 16, 2002


YOUR REF: 09/127,138

OUR DOCKET NO: 24731-500E

NO. OF PAGES INCLUDING THIS PAGE: 11

Dr. Schwadron: Per your request, please find enclosed the faxed copy of Office Action received from USPTO on 10/09/01 and our *Response to Office Action dated 1/10/02*. If you have any further questions please do not hesitate to contact me.

Sincerely,


Cindy Koppelman
Patent Assistant
858-450-8451

SPECIAL INSTRUCTIONS: Please confirm receipt of the attached document by date-stamping the first page as received and faxing it to us or by calling the sender. Thank you.

Please contact the above noted-sender or Debra Walker at Tel. No. (858) 450-8400 or Fax No. (858) 587-5960 or 587-5360 if you DO NOT receive all pages.

Heller Ehrman White & McAuliffe LLP 4350 La Jolla Village Drive, 7th Floor, San Diego, CA 92122-1246 www.hewm.com

San Francisco Silicon Valley Los Angeles San Diego Seattle Portland Anchorage New York Washington D.C. Montgomery Co., MD. Madison WI
Hong Kong Singapore *Affiliated Offices:* Frankfurt Milan Paris Rome

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gruenberg, M.
Serial No.: 09/127,138
Filed: July 31, 1998
For: **AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS
TO TREATMENT OF HUMAN
DISEASE**
Art Unit: 1644
Examiner: Schwadran, R.

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

10/10/2001
Date

Kelly Fischer

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is a Supplemental Amendment responsive to the Paper, received on October 9, 2001, and supplemental to the response, mailed November 13, 2000, to the Office Action, mailed May 15, 2000. If a Petition for extension of time is needed, this paper is to be considered such Petition.

- ☒ The Commissioner is hereby authorized to charge any fee, including any submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Registration No. 33,779

Attorney Docket 24731-500E
Address all correspondence to:
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, Suite 600
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
E-mail: sseidman@HEWM.com

04/16/2002 10:38 FAX 8584508

HELLER EHRMAN SD

005

THE STAMP OF THE U.S. PATENT AND TRADEMARK OFFICE AFFIXED
HERETO WILL BE EVIDENCE OF RECEIPT OF THE FOLLOWING SENT
VIA FIRST CLASS [PRIORITY] MAIL ON 10/10/01:

CLIENT NO.: 24731-500E SLS:SP:kml
ENCLOSURES: TRANSMITTAL LETTER (in duplicate);
SUPPLEMENTAL AMENDMENT (2 pages);
ATTACHMENT TO SUPPLEMENTAL AMENDMENT;
and RETURN POSTCARD.
APPLICANT: GRUENBERG, M.
SERIAL NO.: 09/127,138 FILING DATE: 07/31/98
FOR: AUTOLOGOUS IMMUNE CELL THERAPY: CELL
COMPOSITIONS, METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE

PLEASE STAMP HERE (THANK YOU):

THE STAMP OF THE U.S. PATENT AND TRADEMARK OFFICE AFFIXED
HERETO WILL BE EVIDENCE OF RECEIPT OF THE FOLLOWING SENT
VIA FIRST CLASS [PRIORITY] MAIL ON 10/10/01:

CLIENT NO.: 24731-500E SLS:SP:kml
ENCLOSURES: TRANSMITTAL LETTER (in duplicate);
SUPPLEMENTAL AMENDMENT (2 pages);
ATTACHMENT TO SUPPLEMENTAL AMENDMENT;
and RETURN POSTCARD.
APPLICANT: GRUENBERG, M.
SERIAL NO.: 09/127,138 FILING DATE: 07/31/98
FOR: AUTOLOGOUS IMMUNE CELL THERAPY: CELL
COMPOSITIONS, METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE

PLEASE STAMP HERE (THANK YOU):



FILE COPY

Received from < 8584508499 > at 4/16/02 2:40:07 PM [Eastern Daylight Time]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MICHEAL L. GRUENBERG

Serial No.: 09/127,138

Filed: July 31, 1998

For: AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE

Art Unit: 1644

Examiner: Schwadron, R

I hereby certify that this paper and the attached
papers are being deposited with the United States
Postal Service as first class mail in an envelope
addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

10/10/01
Date*Kelly Fisher*
Kelly Fisher

SUPPLEMENTAL AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Responsive to the Paper, received on October 9, 2001, and supplemental
to the response, mailed November 13, 2000, to the Office Action, mailed May
15, 2000, please amend the above-captioned application as follows:

IN THE CLAIMS:

Please replace claims 124 and 126 with the following amended claims (a
marked-up copy of the amended claims is attached to this Supplemental
Amendment):

124. (Amended) A method for altering the regulatory balance of immune
cells in a human, comprising administering to the human a composition
comprising at least 10^{10} Th1 cells.

126. (Twice Amended) The method of claim 48, wherein at least 10^{11}
cells are reinfused.